Sign In
Buy EYPT
$12.34
-0.190 (-1.52%)
At Close: Jun 03, 2026
EyePoint Pharmaceuticals to Present Data at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting
07:00am, Friday, 17'th Sep 2021
WATERTOWN, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the liv
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q2 2021 Results - Earnings Call Transcript
02:48pm, Wednesday, 04'th Aug 2021
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q2 2021 Results - Earnings Call Transcript
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates
09:55am, Wednesday, 04'th Aug 2021
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 22.22% and 2.42%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals Announces Renowned Scientists to Join New Executive Scientific Advisory Board
07:00am, Monday, 02'nd Aug 2021
Chaired by Dr. Carl Regillo, illustrious leader in retinal surgery Chaired by Dr. Carl Regillo, illustrious leader in retinal surgery
EyePoint Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 4, 2021
08:00am, Wednesday, 28'th Jul 2021
WATERTOWN, Mass., July 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the
EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU®
07:00am, Tuesday, 20'th Jul 2021
WATERTOWN, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the
WATERTOWN, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the
EyePoint Pharmaceuticals Joins Russell 2000® and Russell 3000® Index
07:00am, Monday, 28'th Jun 2021
WATERTOWN, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2021 Results - Earnings Call Transcript
01:33pm, Wednesday, 05'th May 2021
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2021 Results - Earnings Call Transcript
EyePoint Pharmaceuticals's Earnings Outlook
10:34am, Tuesday, 04'th May 2021
On Wednesday, May 05, EyePoint Pharmaceuticals (NASDAQ:EYPT) will release its latest earnings report. Decipher the announcement with Benzinga's help.
EyePoint Pharmaceuticals End Of Year Earnings Call Analysis
02:51pm, Thursday, 22'nd Apr 2021
EyePoint Pharmaceuticals End Of Year Earnings Call Analysis
EyePoint Pharmaceuticals' (EYPT) CEO Nancy Lurker on Q4 2020 Results - Earnings Call Transcript
01:53pm, Thursday, 04'th Mar 2021
EyePoint Pharmaceuticals' (EYPT) CEO Nancy Lurker on Q4 2020 Results - Earnings Call Transcript
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates
09:08am, Thursday, 04'th Mar 2021
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -324.44% and -70.39%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for th
4 Stocks in the Limelight on New Analyst Coverage
10:36am, Wednesday, 17'th Feb 2021
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Stamps.com Inc. (STMP), Ribbon Communications Inc. (RBBN), American Software, Inc. (AMSWA) and
EyePoint Pharmaceuticals: Time For Liftoff
08:54pm, Sunday, 14'th Feb 2021
EYPT has had great products for some time now. They finally got their financing in order and the market loved it.
